High-Risk MDS: Where We Are and Where We Are Heading
In this segment, “High-Risk MDS: Where We Are and Where We Are Heading”, Guillermo Garcia-Manero, MD, and David Sallman, MD, discuss emerging data and remaining challenges in the management of higher-risk MDS.
The last few years have seen a plethora of studies in higher-risk MDS. However, survival is still short and therapies that improve outcomes are needed, particularly for patients who experience HMA failure. Results of ongoing phase 3 clinical trials that involve novel agents and combinations are eagerly anticipated and have the potential to change the current standard of care in this molecularly heterogeneous disease.